Steering Committee (SC)

The NBDA Steering Committee serves as the management advisory board for the NBDA.  Its members derive from the various communities invested and/or interested in enhancing the quality of biomarkers and the pace and ultimate success of their development. The SC advises management on the implementation of NBDA’s strategic and resource plans, assists management in setting priorities, reviews project performance, and provides support and leadership for fund raising and partnership development. The SC also reviews and advises management on major projects (e.g., NBDA-Partner demonstration projects), including budget requirements and deliverables.

Anna Barker

Anna D. Barker, PhD
President and Director, National Biomarker Development Alliance; Director, Transformative Healthcare Knowledge Networks; Co-Director, Complex Adaptive Systems; Professor, School of Life Sciences, Arizona State University

As the director and president of the NBDA, Dr. Barker leads the areas of strategic planning, staffing, program development, and implementation. She works closely with the management team, advisors, external experts, and other stakeholders to define the scope of targeted scientific and education projects and to achieve the mission of the NBDA.

Dr. Barker is co-director of Complex Adaptive Systems at Arizona State University (ASU), which serves as an organizing construct to understand and solve multidimensional problems in the biological and social and sciences, such as those represented by the NBDA. In this role, she has directed efforts to develop transformative knowledge networks that leverage convergent knowledge, innovative teams, and novel funding approaches to better prevent and treat acute and chronic diseases. The NBDA will employ this model.

Prior to joining ASU, Dr. Barker served as Deputy Director of the NCI and as Deputy Director of the NCI’s Strategic Scientific Initiatives for several years, where she developed and implemented multidisciplinary and transdisciplinary programs, including the Nanotechnology Alliance for Cancer, The Cancer Genome Atlas (TCGA) (in collaboration with the National Human Genome Research Institute), the Clinical Proteomics Technologies Initiative for Cancer, the Physical Sciences-Oncology Centers, and major national efforts in biospecimen best practices (caHUB) and bioinformatics (caBIG). All of these programs emphasize the synergy of large-scale and individual-initiated research, precompetitive research, public databases, and clinical research to more effectively detect prevent and treat cancer. She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China.

In the biomarker area, Dr. Barker was the founding co-chair of the NCI-FDA Interagency Task Force, founding co-chair of the Cancer Steering Committee of the Foundation for the National Institutes of Health (FNIH) Biomarker Consortium, and founding director of the NBDA. She has a long history in research and in the leadership and management of research and development in the academic, nonprofit, and private sectors. Dr. Barker served as a senior scientist and subsequently as a senior executive at Battelle Memorial Institute for 18 years and cofounded and served as the CEO of a public biotechnology drug development company. She has received a number of awards for her work in support of cancer research, cancer patients, professional and advocacy organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker’s research interests include biomarker discovery and development, complex adaptive systems science, and free-radical biochemistry in cancer etiology and treatment. She completed her M.A. and Ph.D. degrees at The Ohio State University, where she trained in immunology and microbiology.

Steven Averbuch

Steven D. Averbuch, M.D.
Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company

Dr. Averbuch is currently Vice President, Translational Clinical Development & Pharmacodiagnostics, for Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA.  In this role, Steve serves as the Executive Sponsor of the Translational R&D teams across the Full Development and Life Cycle Management pipeline. Steve also leads the Pharmacodiagnostics Center of Excellence with its mission to drive biomarker strategy, optimize biomarker knowledge and tools across all of R&D, and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to BMS products.  

Steve joined BMS in 2006.  Previously he co-led the Oncology early strategy team and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs.  He has made significant Global Clinical Research contributions to business development and he has participated in seven successful acquisitions.

Steve previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine.  He received his M.D. and Internal Medicine training from the University of Illinois, Chicago, and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.

Dr. Averbuch has authored over 60 peer-reviewed publications and book chapters and he is a co-author on one patent.  He is currently on the Personalized Medicine Coalition Board of Directors, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation, and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research, having served on multiple committees for both organizations.

Raymond DuBois

Raymond DuBois, M.D., Ph.D. 
Executive Director, The Biodesign Institute
Arizona State University (ASU)
Co-Leader, Prevention Program, Mayo Clinic

As Executive Director of the Biodesign Institute, Dr. Dubois leads a large group of faculty and staff dedicated to addressing critical global challenges in health care, sustainability, and security through the development of solutions inspired from natural systems.  In addition he serves as the Dalton Chair, School of Health Solutions; Professor, Department of Chemistry and Biochemistry at ASU; and as Co-leader of the Cancer Prevention Program at the Mayo Clinic.  In this latter role, he is actively engaged in enabling the active partnership between ASU and the Mayo Clinic, including the development of a medical school campus. Dr. DuBois is an internationally renowned expert in the molecular and genetic basis for colorectal cancer and continues his research work at Biodesign.

Before joining ASU, he served as Provost and Executive Vice President and professor of cancer medicine and cancer biology at the University of Texas MD Anderson Cancer Center in Houston. He served in various roles at Vanderbilt, including the Division of Gastroenterology, Hepatology, and Nutrition.  His research work led to the discovery of COX-2 inhibitors for the treatment of selected inflammatory diseases.  Dr. Dubois has published extensively and received a numerous awards including the Ellen F. Knisely Distinguished Chair in Colon Cancer Research, Johns Hopkins Society of Scholars, Dorothy P. Landon Cancer Research Prize, and Richard and Hinda Rosenthal Foundation Cancer Research Award.  He is a Fellow of the American Association for the Advancement of Science and is past president of the American Association for Cancer Research.  He received his Ph.D. degree from the University of Texas Southwestern Medical Center and his M.D. from the University of Texas Health Science Center at San Antonio and completed a residency and gastroenterology fellowship at Johns Hopkins.

Kenneth Noonan

Kenneth D. Noonan, Ph.D.
Venture Partner, Advanced Technology Ventures;
Managing Director, TKA Associates, LLC;
Senior Advisor, L.E.K. Consulting LLP, European Biopharmaceuticals & Life Sciences Practice

Ken’s life-long professional focus has been on all aspects of the global life sciences industries.  Currently, Ken is the Managing Director of T/K Associates LLC, a specialist consulting firm dedicated to supporting start-ups in the life sciences space with commercial, financial, and business planning. He is also a Venture Partner at Advanced Technology Ventures (ATV), a well- established U.S. venture fund.  From 2001-2013 Ken was the Senior Partner heading the European Life Sciences Practice at L.E.K. Consulting LLP, a global management consultancy. He remains a Senior Adviser to L.E.K. Consulting LLP. 

Prior to joining L.E.K., Ken was head of the European Pharmaceutical Practice at Booz-Allen and Hamilton.  He began his consulting career in 1990 as Head of the European Life Sciences Practice at The Wilkerson Group, a boutique consultancy providing commercial consulting services to the life sciences industry.   Ken had line management experience at CooperTechnicon, Inc, BBL Microbiology Systems (a division of BectonDickinson), as well as Bethesda Research Labs.

Ken has had significant experience over the last 15 years as a member of the Board of Directors of public and private, U.S., and European life science companies. He currently sits on the board of Kailos Genetics Inc, a development-stage pharmacogenomics company, as well as the Advisory Board of the BioDesign Institute of Arizona State University.  Ken holds a Ph.D. in Biochemistry from Princeton University.

David Parkinson

David R. Parkinson, M.D.
Venture Partner, New Enterprise Associates, Inc.

David R. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making.

Prior to leading Nodality, Dr. Parkinson served in several leadership roles in the pharmaceutical industry, including Senior Vice President, Oncology Research and Development, at Biogen Idec where he oversaw all oncology discovery research efforts and the development; Vice President, Oncology Development, at Amgen;  and Vice President, Global Clinical Oncology Development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix.

Prior to joining the industry, Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves as a member of the National Cancer Policy Forum of the Institute of Medicine; co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium; and Chairman of the AACR Finance Committee. Dr. Parkinson received his M.D. from the University of Toronto and completed a Hematology Fellowship at Royal Victoria Hospital at McGill University and was a Research Fellow at the New England Medical Center at Tufts University.  He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center.

George Poste

George Poste, DVM PhD
Interim Chief Science Officer, National Biomarker Development Alliance; Co-Director, Complex Adaptive Systems; Regents’ Professor and Del E. Webb Chair in Health Innovation, Arizona State University

Dr. Poste serves as the interim Chief Science Officer for the NBDA. In this role, through the NBDA’s think tanks and workshops and literature and other sources, he works closely with the Alliance team to identify and prioritize key barriers in the discovery and development modules of biomarker development. He also creates networks among relevant stakeholders to plan and implement solution strategies for the barriers identified.

Dr. Poste is Regents’ Professor and Del E. Webb Chair of Health Innovation at Arizona State University. He founded and built the Biodesign Institute at ASU and served as its Director from 2003 to 2009. In 2009 he launched the Complex Adaptive Systems (CAS) at ASU, which integrates research across disciplines to study the altered regulation of molecular networks in human diseases to provide a contemporary basis for the development of targeted disease interventions, inclusive of remote monitoring of health status using miniaturized body sensors and mobile devices.

Dr. Poste is a Fellow of the U.K. Royal Society, the Royal College of Pathologists, and the U.K. Academy of Medicine; a Distinguished Fellow at the Hoover Institution, Stanford University; and a member of the Council on Foreign Relations and the U.S. Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security, and health care.

He has published extensively on pharmaceutical technologies, cancer, and infectious diseases.  He was honored in 1999 by Her Majesty, Queen Elizabeth II, as a Commander of the British Empire for his contributions to international health care and security. He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of Burrill and Company and Synthetic Genomics. From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB), where he was associated with the registration of 31 drug, vaccine, and diagnostic products. He has received a number of awards including Scientist of the Year by R&D Magazine; the Einstein Award from the Global Business Leadership Council, 2006; and the Scrip Lifetime Achievement Award, 2009.


Terah A. CrewsTerah A. Crews, A.M., Ed.M.
Special Advisor to the CEO for Ventures, ASU Foundation for A New American University 

As Special Advisor to the CEO of the ASU Foundation, Ms. Crews supports the creation and development of high potential ventures and special projects.  She acts as a liaison between the foundation and special ventures and assists organizations in the design and launch of new programs.  Before joining the ASU Foundation she was an Innovation Fellow under the Office of the President at ASU where she helped assess and launch the president's special initiatives.  She has studied and written about campus and community relations as well as the role of economic engagement in higher education.  She holds Masters degrees from Brown University in History and Harvard University in Higher Education.

Ms. Crews represents the CEO of the ASU Foundation, R.F. “Rick” Shangraw Ph.D. as an ex-officio member of the NBDA steering committee.